Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pavinetant
- Development stage
- Discontinued
- Lead developer
- Tempest Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Pavinetant is a small-molecule, orally active, selective neurokinin 3 (NK3) receptor antagonist. It was originally developed by AstraZeneca and later by Millendo Therapeutics (now Tempest Therapeutics) for the treatment of hot flashes, polycystic ovary syndrome (PCOS), and schizophrenia. The drug acts as an antagonist at the neurokinin 3 receptor (also known as the neuromedin-K receptor or TACR3), which is involved in modulating hormone release and neuronal signaling. Clinical development for all indications was discontinued due to lack of efficacy in schizophrenia and unfavorable risk-benefit profile—including abnormal liver function—in trials for hot flashes and PCOS[2][3][4][7].
- Brand names
- pavinetant
- Other names
- 3-methanesulfonamido-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide
02
Targets
TACR3 (Neurokinin 3 Receptor)
Beyond the preview
Go deeper on pavinetant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pavinetant.